Skip to main content
Evidence Snapshot

Neuromedin-K receptor

CHEMBL4429 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:49:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4429
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neuromedin-K receptor as ChEMBL target CHEMBL4429, mapped to UniProt P29371. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neuromedin-K receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-12
ChEMBL target ID
CHEMBL4429
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
UniProt accession
P29371
Neuromedin-K receptor
UniProt accession via ChEMBL component mapping As of 2026-09-12
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Neuromedin-K receptor matters

As of 2026-09-12

Neuromedin-K receptor is reviewed as Neuromedin-K receptor (UniProt P29371); Neuromedin-K receptor shows approved-linked disease relevance led by Hot flashes. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 1414 compounds, and 262 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Hot flashes

Neuromedin-K receptor shows approved-linked disease relevance led by Hot flashes. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ELINZANETANT, FEZOLINETANT.

Start review with Hot flashes because it currently carries approved-linked support. Linked drugs include ELINZANETANT, FEZOLINETANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 1414 compounds, and 262 assays for this target. The dominant activity type is KI. CHEMBL3736177 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3736177 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Neuromedin-K receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P29371, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Hot flashes is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1414
Total Compounds
262
Total Assays
3
Approved Drugs
IC50: 749.0, KI: 1360.0, EC50: 142.0, KD: 30.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3736177
 11.0 EC50 —
No preferred name
CHEMBL2347491
 10.9 EC50 —
No preferred name
CHEMBL3735159
 10.9 EC50 —
No preferred name
CHEMBL583102
 10.9 EC50 —
No preferred name
CHEMBL3735427
 10.9 EC50 —

Approved Drugs

Structure Compound First Approval
FEZOLINETANT
CHEMBL3608680
 2023
APREPITANT
CHEMBL1471
 2003
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:49:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4429